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Objectives: Following an ischemic insult, cardiac contractile recovery might be perturbed by the release of autacoids, like platelet-
activating factor (PAF), that depress heart function by acting through G protein-coupled receptors (GPCRs). The signaling events
downstream the PAF receptor that lead to the negative inotropic effect are still obscure. We thus investigated whether the GPCR-activated
phosphoisositide 3-kinase g (PI3Kg) could play a role in the cardiac response to PAF. Methods: The negative inotropic effect of PAF was
studied ex vivo, in isolated electrically driven atria and in Langendorff-perfused whole hearts derived from wild-type and PI3Kg-null mice.
Postischemic recovery of contractility was analyzed in normal and mutant whole hearts subjected to 30 min of ischemia and 40 min of
reperfusion in the presence or absence of a PAF receptor antagonist. Results: While wild-type hearts stimulated with PAF showed increased
nitric oxide (NO) production and a consequent decreased cardiac contractility, PI3Kg-null hearts displayed reduced phosphorylation of nitric
oxide synthase 3 (NOS3), blunted nitric oxide production and a complete protection from the PAF-induced negative inotropism. In addition,
Langendorff-perfused PI3Kg-null hearts showed a better contractile recovery after ischemia/reperfusion, a condition where PAF is known to
be an important player in depressing contractility. In agreement with a role of PI3Kg in this PAF-mediated signaling, postischemic contractile
recovery in PI3Kg-null mice appeared overlapping with that of normal hearts treated with the PAF receptor antagonist WEB 2170.
Conclusion: These data indicate a novel PAF-dependent signaling pathway that, involving PI3Kg and NOS3, contributes to postischemic
contractile depression.
D 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Signal transduction; Inotropic agents; Ischemia; Nitric oxide
1. Introduction (PtdIns(3,4,5)P ) [1]. Class I phosphatidylinositol 3-kinaseIn the heart, homeostatic regulation and stress responses
are mainly controlled by the extracellular signals transduced
by G protein-coupled receptors (GPCRs). Upon activation,
these receptors trigger the production of second messengers,
such as the lipid phosphatidylinositol (3,4,5)-trisphosphate0008-6363/$ - see front matter D 2003 European Society of Cardiology. Publish
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selectively phosphorylate the 3V-OH residue of phosphati-
dylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) to form
PtdIns(3,4,5)P3, which serves as a docking site for cyto-
plasmic proteins involved in multiple cellular processes
such as survival, proliferation, cytoskeletal remodeling and
membrane trafficking [2].
Class I PI3Ks consist of dimers that are classified in two
subfamilies depending on their composition and mechanism
of activation (for a review, see Ref. [3]). PI3Ks of the first
subgroup (class IA) are formed by the catalytic subunit
associated with a p85-like regulatory protein docking toed by Elsevier B.V. All rights reserved.
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group is instead characterized by the interaction of the
catalytic subunit with an adaptor called p101 and by the
activation through hg subunits of trimeric G proteins (class
IB). The only class IB member, phosphoisositide 3-kinase g
(PI3Kg), is highly expressed in white blood cells but can be
detected at lower levels in the cardiovascular system [4–6].
We and others recently reported that PI3Kg-deficient mice
were viable and fertile, but displayed defective GPCR
responses to chemoattractants in leukocytes [7–9], to ADP
in platelets [10] and to adenosine in mast cells [11]. On the
other hand, little is known about the role of PI3Kg in the
cardiovascular system [12]. Interestingly, PI3Kg has been
found to be expressed in bovine aortic endothelial cells and to
signal under shear stress to mitogen activated protein kinase
(MAPK) [13]. PI3Kg also appears to control angiotensin-II-
dependent L-type calcium channel activation in vascular
smooth muscle cells [5]. Moreover, PI3Kg has been shown
to be present in cultured cardiomyocytes and to mediate the
ATP-dependent generation of autonomic calcium oscillations
by modulating Tec and Fyn kinases, and phospholipase C g
(PLCg) [4].
In agreement with these findings, we recently showed that
PI3Kg acts as a negative regulator of myocardial contractil-
ity [14]. This suggested that the lack of PI3Kg might lead to
improved heart function in response to GPCR agonists
playing maladaptive roles in cardiac pathologies. Here, we
provide the evidence that PI3Kg-null hearts show improved
contractility in response to platelet-activating factor (PAF), a
GPCR agonist released during ischemia and involved in
depressing postischemic cardiac function.2. Methods
2.1. Mice
PI3Kg-null mice were obtained as previously described
[7]. All experiments were performed with female 8-week-
old wild-type and PI3Kg / mice; both mutant and control
animals were inbred 129 sv. Mice were anesthetized with
avertin and sacrificed by cervical dislocation. Animal
experiments were carried out in compliance with institu-
tional guidelines as well as with Italian and Swiss govern-
ment regulations.
2.2. Analysis of contractility in isolated cardiac muscle
preparations
After sacrifice, heart was rapidly removed, and atria
were dissected free under microscopic control. Tissue
preparations were superfused with a modified Tyrode
solution (154 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1
mM MgCl2, 5.5 mM D-glucose, 5 mM HEPES, adjusted to
pH 7.36 with NaOH and gassed with 100% O2). Cardiac
muscles were equilibrated in modified Tyrode solution forat least 30 min before each experiment, and experiments
were conducted at 37 jC. Atria were driven at a frequency
of 240 beats/min with a pair of electrodes connected to a
302 T Anapulse Stimulator via a 305-R Stimulus Isolator
(W. P. Instruments, New Haven, CT, USA) operating in
constant current mode. Isometric twitches were measured
by a Harvard Isometric Transducer 60-2997 and were
recorded and analyzed using a custom-made Labview
based VI (National Instruments, USA) on an Apple Power-
Mac. Endocardial endothelium was removed as previously
described [15]. Briefly, cardiac preparations were treated
with Tyrode solution containing 0.5% Triton X-100 for 1
or 2 s and then recovered in Triton-free Tyrode solution for
30 min.
2.3. PAF-induced Akt/PKB and nitric oxide synthase 3
(NOS3) phosphorylation and NO production
Isolated mouse hearts were washed with PBS, weighed
and incubated in PBS–BSA 0.25% for 2 min in ice. The
hearts were transferred at 37 jC and then stimulated 10 min
with PAF 1 AM or PBS–BSA 0.25%. Immediately thereaf-
ter, hearts were frozen in liquid nitrogen.
For immunodetection of proteins, frozen heart tissue
samples were homogenized by sonication in 50 mM Tris
pH 7.5, 150 mM NaCl containing 1% NP-40 for immuno-
precipitation and 1% SDS for Western blot. Immunopre-
cipitation of PI3Kg was performed using a rabbit
polyclonal antibody and detected with a monoclonal anti-
body (both kindly provided by Reinhard Wetzker, Jena,
Germany). Western blots for analysis of phosphorylation
were probed overnight at 4 jC with polyclonal antibodies
that recognize phosphorylated Akt (Ser-473), phosphory-
lated NOS3 (Ser-1177), total Akt or a monoclonal antibody
recognizing total NOS3 (all from Cell Signaling Techno-
logy, Beverly, MA).
For the evaluation of NO production, frozen hearts were
rapidly minced, placed in ice-cold PBS (total volume 1.5
ml) and immediately homogenized. Samples were centri-
fuged at 100000 g for 20 min, and the supernatants were
stored at  80 jC. Cardiac NO content was measured with a
fluorimetric assay kit (Cayman, Ann Arbor, MI) that detects
nitrite/nitrate NO degradation products following the manu-
facturer’s instructions. Assays were repeated three times
with reproducible results. For the analysis of pertussis toxin
effects on PAF-dependent NO production, mice were ad-
ministered either pertussis toxin 30 Ag/kg (Sigma) in saline
or saline alone by intraperitoneal injection. This protocol is
known to specifically inactivate inhibitory guanine nucleo-
tide proteins (Gi and Go) in cardiac tissue [16]. Hearts were
collected 24 h later and treated as above.
2.4. Model of myocardial ischemia/reperfusion injury
The isolated mouse hearts were dissected and weighed
(weight appeared similar in the two genotypes: 232.5F 13.3
Fig. 2. Effects of PAF-mediated NO production on cardiac inotropism. (a)
Analysis of the role of NO in the PAF-dependent induction of negative
inotropism in electrically paced (240 beats/min) atrial muscles. Bars (white,
wild-type; black, PI3Kg /) represent force of contraction of electrically
paced (240 beats/min) atrial muscles in % of the basal value after stimulation
with 1 AM PAF in the presence or absence of the NOS inhibitor L-NAME (1
mM; n= 4) and of the NO donor sodium nitroprusside (SNP; 1 AM; n= 4 for
both genotypes). Contractile force baseline values were 31.7F 3.2 and
33.8F 4.3 mg for wild-type and mutant cardiac preparations, respectively.
The PAF-mediated negative inotropism results inhibited by L-NAME in
wild-type samples and restored by SNP in PI3Kg /  atria. **P<0.01.
Fig. 1. PAF-dependent effects on cardiac contractility. (A and B) Representative traces of the contractile force (arbitrary units) generated by wild-type (A) and
PI3Kg /  (B) electrically paced (240 beats/min) atrial muscles exposed to 1 AM PAF. (C) Summary of PAF (1 AM)-mediated effects on contractility of wild-
type (white bar; n= 6) and PI3Kg /  (black bar; n= 5) atria. The hatched bar corresponds to wild-type samples (n= 3) treated with PAF in the presence of the
PAF receptor antagonist WEB 2170 (3 AM). Bars represent force of contraction in % of the basal value. Baseline values of contractile force were 30.8F 4.3 and
34.0F 5.4 mg for wild-type and mutant atria, respectively. Treatment of wild-type isolated atria with WEB 2170 did not significantly change baseline
contractility. Statistical difference of wild-type versus mutant as determined by ANOVA with Newmann–Keuls post hoc test: **P < 0.01.
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respectively). Hearts were mounted on a Langendorff per-
fusion apparatus, and perfused at a constant flow rate (12
ml/min/g of wet weight) using a peristaltic pump with
modified Tyrode solution warmed to 37 jC and gassed with
100% O2. The force of contraction was monitored through a
hook attached to the LV apex under 1 g of preload. Pacing
electrodes were inserted in the right ventricle and pacing
was adapted to maintain a heart rate of 240 beats/min. After
stabilization, the hearts were subjected to 30 min ischemia
with coronary flow reduced to 3% of the control preische-
mic value, followed by 40 min of reperfusion at the original
flow rate. Controls were perfused continuously for the same
amount of time. Left ventricular contractile force was
measured with a force–displacement transducer (Harvard
Isometric Transducer 60-2997) attached to the apex through
a metal hook. The ventricular force signal was digitally
processed to yield peak systolic contractile force, first
derivative of contractile force development or relaxation
over time (F dF/dt). In experiments with the PAF receptor
antagonist, hearts were perfused for 10 min before ischemia
and during the ischemia/reperfusion with Tyrode solution
containing 3 AM WEB 2170 (Boehringer Ingelheim, Ger-
many). During the 10 min of pretreatment, this concentra-
tion of antagonist did not significantly alter cardiac
performance.
2.5. Statistical analysis
Data are expressed as the meanF S.E.M. Comparisons
used unpaired t test for differences between wild-type and
PI3Kg-deficient mice, paired t test, repeated-measures two-
way ANOVA followed by Bonferroni post hoc test or one
way ANOVA followed by Newmann–Keuls post hoc test as
appropriate. P value of < 0.05 was assigned statistical
significance.
G. Alloatti et al. / Cardiovascular R3. Results
3.1. Protection from PAF-induced cardiac contractile
depression in PI3Kc-null hearts
In response to ischemia, cardiac function is depressed
by the release of autacoids like PAF, a potent inflammatory
mediator [17] known to induce a negative inotropic effect
[18,19]. PAF binds to a GPCR and activation of PI3Kg
could be a possible downstream signaling event. To
investigate whether PI3Kg played a role in mediating
PAF-dependent effects on cardiac function, the contractile
response to PAF stimulation was evaluated in electrically
paced wild-type and PI3Kg-null cardiac muscles. In wild-
type atria, PAF induced the expected negative inotropic
effect, reducing contractility to 60% of its basal value (Fig.
1A and C). Pretreatment with the PAF receptor antagonist
WEB 2170 inhibited in wild-type cardiac muscle prepara-
tions the PAF-dependent negative inotropism, thus demon-
strating the specific involvement of the PAF receptor in
this process (Fig. 1C). Strikingly, when PAF was admin-
istered to PI3Kg-null atria the reduction of contractility
could not be detected (Fig. 1B and C). Identical results
were obtained studying the effect of lower doses of PAF
(0.1 AM) on Langendorff-perfused hearts: wild-type sam-
ples showed a 54.3F 6.1% reduction of contractility
(n = 6), and PI3Kg-deficient hearts were not affected
(106.8F 7.4% of basal contractility, n = 4; P < 0.01, wild-
type versus mutant). These data thus demonstrate that
PI3Kg relays signals mediating the PAF-mediated negative
inotropic response.Fig. 3. Involvement of PI3Kg in the PAF-dependent NO production in hearts. (A)
type (lighter bars) and PI3Kg /  (darker bars) hearts. Co (gray bars; n= 4 for eac
bars; n= 3 for each genotype), nitrate/nitrite concentration after treatment with pe
nitrate/nitrite concentration after stimulation with 1 AM PAF; PTX+PAF (hatc
stimulated hearts pretreated with pertussis toxin. PAF-mediated NO producti
Immunoprecipitation analysis of PI3Kg expression in wild-type and PI3Kg-defic
line expressing PI3Kg (U937), and from wild-type (+/+) and PI3Kg /  ( / )
after PAF stimulation of wild-type (+/+) and PI3Kg /  ( / ) hearts. Co
phosphorylation of PKB/Akt and NOS3.3.2. Defective PAF-induced NO production in hearts
lacking PI3Kc
It has previously been suggested that PAF modulates
cardiac function by triggering the production of nitric oxide
(NO) [20]. Concomitant administration of PAF and of the
NO synthesis inhibitor N(N)-nitro-L-arginine methyl ester
(L-NAME) completely prevented the negative inotropic
effect. The use 1 mM of N(G)-methyl-L-arginine (L-
NMMA), a NO synthase inhibitor without antimuscarinic
activity, provided identical results: 91.0F 5.0% of contrac-
tility before PAF administration in wild-type atria treated
with L-NMMA and PAF. Addition of 1 mM L-arginine to L-
NMMA-treated cardiac samples restored the effect of PAF
(63.3F 1.5% of contractility before PAF). Conversely,
administration of the NO donor sodium nitroprusside
(SNP) induced a comparable reduction of contractility in
wild-type and PI3Kg-null cardiac muscle (Fig. 2). In
addition, treatment of wild-type atria with Triton X-100 to
remove endocardial endothelium did not modify the nega-
tive inotropic effect exerted by PAF (59.5F 2% of basal
contractility, n = 6). These results suggest that myocardial
PI3Kg is necessary for PAF-induced NO release. To study
if the effect of PAF on contractility were depending on
adenosine or acetylcholine release, atria were pretreated
with inhibitors of the adenosine A1 (8-cyclopentyl-1,3-
dipropylxantine, DPCPX 10 AM) and acetylcholine musca-
rinic (Atropine 5 AM) receptors. Neither A1 nor M receptors
blockade modified the negative inotropic response to PAF
(59.0F 10.0% and 59.5F 6.5% of basal contractility, re-
spectively; n = 4) in wild-type cardiac preparations, thus
esearch 60 (2003) 242–249 245I
Measurement of the PAF-dependent total nitrite/nitrate production in wild-
h genotype), nitrate/nitrite concentration in resting condition; PTX (crossed
rtussis toxin (PTX); PAF (white and black bars; n= 6 for each genotype),
hed bars; n= 4 for each genotype), nitrate/nitrite concentration in PAF-
on in the heart is blocked by PTX and by the lack of PI3Kg. (B)
ient murine hearts. Displayed are immunoprecipitatates from a control cell
hearts. (C) Detection of the phosphorylation state of PKB/Akt and NOS3
, unstimulated control. PI3Kg is needed for PAF-dependent maximal
Fig. 4. Cardiac functions during ischemia and reperfusion in Langendorff-
perfused PI3Kg-deficient and control hearts. Wild-type (white diamonds;
n= 5) and PI3Kg /  (black squares; n= 5) hearts were perfused in
Langendorff mode with for 20 min and then subjected to 30 min of
ischemia, followed by 40 min of reperfusion. (A) Left ventricular systolic
contractile force as a percentage of baseline. (B) Rate of left ventricular
maximal contractile force development over time ( + dF/dt). (C) Rate of left
ventricular maximal relaxation over time ( dF/dt). Baseline force of
contraction was 1616.9F 123.1 and 1763.3F 156.4 mg for wild-type and
mutant hearts, respectively. Maximal contraction velocity was 28.8F 2.3
and 31.4F 3.3 g/s for wild-type and mutant hearts, respectively. Maximal
relaxation velocity was 23.2F 2.8 and 25.4F 3.5 g/s for wild-type and
mutant hearts, respectively. Statistical difference of wild-type versus
mutant: P< 0.001 as determined by two-way ANOVA.
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production.
Measurement of the total concentration of NO degrada-
tion products nitrite/nitrate in explanted wild-type hearts
showed that PAF stimulation induces a threefold increase
over the basal level of nitrite/nitrate concentration per gram
of wet tissue (Fig. 3A). Since the pretreatment of mice with
pertussis toxin blocks the PAF-mediated NO production,
this process depends on a signaling pathway activating Gi
(Fig. 3A). This effect was specific as treatment with PTX
alone and in combination with PAF of wild-type and mutant
cardiac tissue was equal to the untreated controls. Strikingly,
the PAF-dependent NO production also requires PI3Kg
activity because, in PI3Kg-null mice, PAF did not increase
nitrite/nitrate concentration above background levels (Fig.
3A). To elucidate the mechanism underlying these effects
we analyzed the phosphorylation of the endothelial NO
synthase. Recent reports indicate that the protein kinase B
(PKB)/Akt, which is phosphorylated and activated in a
PI3K-dependent way, might phosphorylate and activate
the NO synthase type 3 (NOS3) [21,22], an enzyme
constitutively expressed by cardiomyocytes [23]. Consis-
tently, PAF stimulation of hearts expressing PI3Kg (Fig. 3B)
caused both PKB/Akt and NOS3 phosphorylation (Fig. 3C).
By contrast, mutant hearts lacking PI3Kg (Fig. 3B) showed
a marked reduction in PKB/Akt and NOS3 phosphorylation
after PAF administration (Fig. 3C). These data thus indicate
that PAF triggers NO production through a Gi-dependent
pathway, involving the PI3Kg-dependent phosphorylation
of PKB/Akt and NOS3.
3.3. Improved postischemic recovery in PI3Kc-null hearts
Because contractility is a critical parameter of cardiac
function that seriously deteriorates after ischemia, we
assessed the impact of the lack of PI3Kg in the postischemic
recovery of hearts. To minimize indirect effects due to
impaired inflammatory responses of PI3Kg-null mice [7–
9], contractile force during ischemia/reperfusion was studied
ex vivo in Langendorff-perfused hearts. Preischemic cardiac
function of PI3Kg-null hearts was comparable to that of wild-
type controls and during the period of global ischemia,
ventricular developed force was equally depressed in both
genotypes. However, after reperfusion, the recovery of con-
tractile force, the rate of contractile force development and
the rate of ventricular relaxation were significantly improved
in PI3Kg-deficient hearts compared to wild-type controls
(P < 0.001, P= 0.02, P= 0.01, respectively, by two-way
ANOVA). At 20 min of reperfusion, wild-type hearts showed
a maximal contractile recovery of 60%, while mutant hearts
reached 80% of the preischemic value (Fig. 4A–C; P < 0.05,
wild-type versus mutant hearts by Bonferroni post hoc test).
This highlights a fundamental role of PI3Kg in depressing
cardiac function in postischemic stress conditions.
To test whether this could be due to a decreased respon-
siveness to PAF, we analyzed the contractile recovery ofwild-type and mutant mouse hearts subjected to ischemia/
reperfusion after incubation with the PAF receptor antagonist
WEB 2170. Interestingly, in wild-type cardiac muscles, this
treatment caused a marked increase in postischemic contrac-
tility that was overlapping with that detected in PI3Kg-null
Fig. 5. Role of PAF in the alteration of cardiac contractility after ischemia/
reperfusion. Wild-type (white squares/circles; n= 5) and PI3Kg /  (black
squares/circles; n= 5) hearts were perfused in Langendorff mode with for
20 min and then subjected to 30 min of ischemia, followed by 40 min of
reperfusion. Hearts of both genotypes were incubated with (circles) or
without (squares) the PAF receptor antagonists WEB 2170 (3 AM) 10 min
before ischemia. Left ventricular systolic contractile force is expressed as a
percentage of baseline. Prior to reperfusion, contractile force was identical
in all samples (1691.9F 137.3 and 1722F 141.8 mg for wild-type and
mutant hearts, respectively). No significant statistical difference could be
detected among untreated mutant hearts and WEB 2170-treated wild-type
and mutant hearts.
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WEB 2170 did not exert any further improvement in the
contractile recovery (Fig. 5) suggests that the increased
postischemic cardiac response of hearts lacking PI3Kg was
caused by the absence of response to PAF.
Experiments performed on isolated atria stimulated with
PAF strongly suggested a link between the PI3Kg-dependent
nitric oxide production and the depression of cardiac con-
tractility. To verify if PI3Kg acts to cause postischemic
injury through the activation of NO release, wild-type isolate
hearts were subjected to ischemia/reperfusion in the presence
of the NOS inhibitor L-NMMA (10 AM). In agreement with
the proposed mechanism, the blockade of NO synthesis in
wild-type perfused hearts restored postischemic function
(75.0F 7.2% and 68.0F 6.5% of basal contractility at 20
and 30 min of reperfusion, respectively) to a similar extent of
that detected in PI3Kg-null isolated hearts.4. Discussion
PAF is a potent biological mediator of inflammation that
has been shown to be released in significant amounts during
ischemia/reperfusion [24–26]. In normal conditions, PAF is
present in minimal concentrations but can be released ininflamed tissues by activated neutrophils, monocytes or
endothelial cells [17]. The receptor for PAF belongs to the
GPCR superfamily [17] and is present on cardiomyocytes
where it relays signals causing a negative inotropic effect
[27,28]. In the ischemic heart disease, PAF is considered as
the major GPCR agonist depressing myocardial contractility
and thus causing further distress to the ischemic organ
[18,19,29].
Decreasing PAF production has proven to be effective in
the protection from myocardial ischemia/reperfusion injury
[30–32]. However, the identification of signaling events
downstream PAF receptor activation might provide novel
clues to develop more effective therapeutic intervention.
Here, we defined a specific role of PI3Kg in the control
of PAF-mediated reduction of cardiac contractility: hearts
from mice lacking PI3Kg appeared completely protected
from the negative inotropic effect triggered by PAF. Inter-
estingly, in wild-type hearts, the response to PAF was found
mediated by the production of NO that required PI3Kg for
its PAF-mediated production. This finding is consistent with
previous reports indicating that the release of NO could play
a crucial role in the cardiac effects of PAF [20,33] and is
further supported by our results indicating that L-NAME and
L-NMMA completely blocks the negative inotropism in-
duced by PAF. Our observations showing that stimulation of
hearts lacking PI3Kg with the NO donor SNP normally
inhibits contractility further demonstrated that the signaling
pathway triggered by NO is intact in mutant cardiac muscles
and that PI3Kg functions upstream NO production. The
PAF receptor can be coupled to both Gq and Gi types of G
proteins to exert different biological responses [34]. Our
data showing that blocking Gi with pertussis toxin inhibits
PAF-induced NO production demonstrates that, in the heart,
this pathway exclusively involves the Gi-coupled PAF
receptor. In conclusion, these results strongly suggest a
novel PAF-induced signal transduction mechanism impli-
cating a Gi-dependent activation of PI3Kg and a consequent
phosphorylation of PKB/Akt and NOS3.
In this study, we reported that mice lacking PI3Kg show a
better contractile recovery after a global ischemic insult.
Using a PAF antagonist in wild-type murine hearts subjected
to ischemia/reperfusion we found that, in the mouse, most of
the depression of postischemic contractility is due to the
action of this autacoid. Interestingly, we also found that the
protection exerted by the PAF receptor antagonist in wild-
type hearts is very similar to that detected in hearts lacking
PI3Kg. This observation, together with the finding that the
PAF receptor antagonist did not further increase the contrac-
tile recovery in mutant hearts, strongly suggests that the
unresponsiveness to PAF, caused by the lack of PI3Kg, is the
major cause of the improved postischemic contractility of
mutant hearts. In addition, we provided evidence that most of
the contractile depression after reperfusion is mediated by
the release of NO, thus suggesting that the improved perfor-
mance detected in mutant hearts involves the lack of activa-
tion of a signaling cascade that causes, through PAF release
G. Alloatti et al. / Cardiovascular Research 60 (2003) 242–249248and PI3Kg activation, increased NO production. Indeed, this
is in agreement with previous reports indicating that block-
ade of NOS enzymes in the postischemic heart of rats causes
an increased contractile recovery [35]. Our findings thus
indicate that, in the present experimental setting, PAF and
PI3Kg-mediated signal transduction play a fundamental role.
Nevertheless, several other causes for postischemic func-
tional depression have been reported so far, including free
radicals, KATP channels and h-adrenergic signaling. Al-
though our data tend to exclude the involvement of these
factors, it cannot, however, be excluded that in an in vivo
context, other pathophysiologic processes are more impor-
tant in causing postischemic decrement of cardiac function.
Consistently with this hypothesis, deletion of the NOS3 gene
in mice causes contrasting results depending on the presence
or on the absence of blood perfusion in the heart. Although
isolated and Langendorff-perfused NOS3-deficient hearts
show an increased contractile recovery after ischemia [36],
temporary coronary artery occlusion in vivo causes exacer-
bation of the postischemic recovery and a larger infarct size
[37]. Further studies will thus be required to asses the role of
PI3Kg in an in vivo model of cardiac ischemia/reperfusion.
Nevertheless, the data in the present report indicate that
PI3Kg plays a crucial role in the contractile dysfunction
following ischemia/reperfusion, possibly suggesting that
modulation of PI3Kg activity might provide new valuable
therapeutic strategies to improve heart performance after an
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